ES2572703T3 - Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina - Google Patents

Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina Download PDF

Info

Publication number
ES2572703T3
ES2572703T3 ES12791862.1T ES12791862T ES2572703T3 ES 2572703 T3 ES2572703 T3 ES 2572703T3 ES 12791862 T ES12791862 T ES 12791862T ES 2572703 T3 ES2572703 T3 ES 2572703T3
Authority
ES
Spain
Prior art keywords
triazol
morpholin
benzyl
methanone
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12791862.1T
Other languages
English (en)
Spanish (es)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2572703T3 publication Critical patent/ES2572703T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES12791862.1T 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina Active ES2572703T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/IB2011/054976 2011-11-08
IB2011054976 2011-11-08
PCT/IB2012/056218 WO2013068935A1 (en) 2011-11-08 2012-11-07 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
ES2572703T3 true ES2572703T3 (es) 2016-06-01

Family

ID=47258050

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12791862.1T Active ES2572703T3 (es) 2011-11-08 2012-11-07 Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina

Country Status (28)

Country Link
US (1) US9150566B2 (enExample)
EP (1) EP2776430B1 (enExample)
JP (1) JP5718535B2 (enExample)
KR (1) KR101676930B1 (enExample)
CN (1) CN103917538B (enExample)
AR (1) AR088692A1 (enExample)
AU (1) AU2012335194B2 (enExample)
BR (1) BR112014010617B1 (enExample)
CA (1) CA2846568C (enExample)
CL (1) CL2014000659A1 (enExample)
CY (1) CY1117638T1 (enExample)
DK (1) DK2776430T3 (enExample)
EA (1) EA024106B1 (enExample)
ES (1) ES2572703T3 (enExample)
HR (1) HRP20160678T1 (enExample)
HU (1) HUE029239T2 (enExample)
IL (1) IL232462A (enExample)
IN (1) IN2014CN04127A (enExample)
MX (1) MX343837B (enExample)
MY (1) MY167791A (enExample)
PH (1) PH12014500852A1 (enExample)
PL (1) PL2776430T3 (enExample)
SG (1) SG11201401665WA (enExample)
SI (1) SI2776430T1 (enExample)
TW (2) TWI565703B (enExample)
UA (1) UA112317C2 (enExample)
WO (1) WO2013068935A1 (enExample)
ZA (1) ZA201404189B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863413A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
MY179862A (en) 2013-12-03 2020-11-18 Idorsia Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
WO2015087853A1 (ja) * 2013-12-13 2015-06-18 大正製薬株式会社 オキサジナン化合物の結晶形及びその製造方法
JP2017024990A (ja) * 2013-12-13 2017-02-02 大正製薬株式会社 オキサゾリジン及びオキサジナン誘導体
WO2015174532A1 (ja) * 2014-05-16 2015-11-19 国立大学法人 東京大学 うつ治療剤
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
WO2016095205A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
CN104557744B (zh) * 2014-12-23 2017-04-12 广东东阳光药业有限公司 一种三氮唑化合物的制备方法
AU2016360245B2 (en) 2015-11-23 2020-07-09 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof
AU2017217931B2 (en) 2016-02-12 2020-10-22 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
LT3619199T (lt) 2017-05-03 2021-09-27 Idorsia Pharmaceuticals Ltd 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba
WO2020099511A1 (en) * 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
GB201901142D0 (en) 2019-01-28 2019-03-20 Heptares Therapeutics Ltd OX1 Antagonists
CA3206675A1 (en) 2021-02-02 2022-08-11 Markus Von Raumer A crystalline form of (4-methyl-2-[1,2,3]triazol-2-yl-phenyl)-[(r)-3-(3-[1,2,3]triazol-2-yl-benzyl)-morpholin-4-yl]-methanone
AR129309A1 (es) * 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
CN115947697A (zh) * 2022-12-28 2023-04-11 苏州汉德创宏生化科技有限公司 一种3-氧代吗啉-4-羧酸叔丁酯的合成方法
JPWO2024214321A1 (enExample) * 2023-04-10 2024-10-17
GB202311281D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311280D0 (en) 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130432A (en) 1990-12-21 1992-07-14 Syntex (U.S.A.) Inc. Process for preparing cyclic amines and intermediate products thereof
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
WO2002089800A2 (en) * 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
CZ20033437A3 (cs) * 2001-06-28 2004-09-15 Smithkline Beecham P.L.C. N-Aroylové cyklické aminové deriváty jako antagonisté orexinového receptoru
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
CA2557163C (en) 2004-03-01 2011-08-16 Idorsia Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
GB0620818D0 (en) 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
EP2349270B1 (en) * 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
US8710076B2 (en) 2008-10-21 2014-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506374A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
US20100144760A1 (en) 2008-12-02 2010-06-10 Giuseppe Alvaro Novel compounds
AU2009324238A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
JP5847087B2 (ja) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ.ベー. オレキシン受容体調節因子としての縮合複素環式化合物
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ME03452B (me) 2009-10-23 2020-01-20 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora

Also Published As

Publication number Publication date
MX343837B (es) 2016-11-24
BR112014010617A2 (pt) 2017-04-25
PH12014500852A1 (en) 2016-03-02
TWI565703B (zh) 2017-01-11
SI2776430T1 (sl) 2016-06-30
CA2846568C (en) 2020-01-14
SG11201401665WA (en) 2014-09-26
CN103917538A (zh) 2014-07-09
HRP20160678T1 (hr) 2016-07-15
AU2012335194B2 (en) 2017-05-25
HK1199022A1 (zh) 2015-06-19
IL232462A (en) 2016-11-30
JP2014532753A (ja) 2014-12-08
EA024106B1 (ru) 2016-08-31
JP5718535B2 (ja) 2015-05-13
US20150158855A1 (en) 2015-06-11
TWI555747B (zh) 2016-11-01
CN103917538B (zh) 2016-08-24
NZ625896A (en) 2016-04-29
IN2014CN04127A (enExample) 2015-07-10
KR20140096338A (ko) 2014-08-05
TW201632517A (zh) 2016-09-16
CA2846568A1 (en) 2013-05-16
EA201400553A1 (ru) 2014-10-30
UA112317C2 (uk) 2016-08-25
BR112014010617B1 (pt) 2021-12-14
KR101676930B1 (ko) 2016-11-16
MX2014005635A (es) 2014-06-23
IL232462A0 (en) 2014-06-30
CY1117638T1 (el) 2017-04-26
AU2012335194A1 (en) 2014-07-03
TW201323421A (zh) 2013-06-16
WO2013068935A1 (en) 2013-05-16
HUE029239T2 (en) 2017-02-28
US9150566B2 (en) 2015-10-06
ZA201404189B (en) 2017-08-30
CL2014000659A1 (es) 2014-08-18
AR088692A1 (es) 2014-06-25
EP2776430B1 (en) 2016-03-16
MY167791A (en) 2018-09-26
EP2776430A1 (en) 2014-09-17
BR112014010617A8 (pt) 2017-12-26
PL2776430T3 (pl) 2016-09-30
DK2776430T3 (en) 2016-05-09

Similar Documents

Publication Publication Date Title
ES2572703T3 (es) Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina
TWI694076B (zh) 三唑并嘧啶化合物及其用途
EP2785713B1 (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
CN107787323B (zh) 用于抑制shp2活性的化合物和组合物
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
WO2013054291A1 (en) Novel oxazine derivatives and their use in the treatment of disease
BR112014004310B1 (pt) Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto
KR20140015267A (ko) 진통, 정신질환, 인지장애 또는 알츠하이머병의 치료용 알파-7 니코틴 수용체 수식물질
JP2018016544A (ja) 新規ジアザビシクロ[2.2.2]オクタン誘導体
BR112018016446B1 (pt) Composto de piperidina halo-substituída, composição farmacêutica compreendendo dito composto e uso terapêutico dos mesmos
KR20150130413A (ko) 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
CN107207516B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
WO2024086179A1 (en) Pyrimidine sgc stimulators
WO2014081619A1 (en) Pyrimidine pde10 inhibitors
JP2025502326A (ja) デオキシシチジンキナーゼ阻害剤
JP2025537514A (ja) 新規ジアシルグリセリドo-アシルトランスフェラーゼ2阻害薬としてのイミダゾピリジン誘導体及びイミダゾピリダジン誘導体の調製
HK1199022B (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
HK1237764A1 (en) Heteroaryl compounds for kinase inhibition